Buzzberg Cup Live

My Favorite 4 Sectors For The Rest Of 2026

Quoth the Raven · QTR’s Fringe Finance · July 05, 2026 at 13:50 · ⏱ 1 min read  | Read on Substack ↗
Summary
The author highlights psychedelics as a top-performing call in 2026, with specific stocks up 100-200% YTD and the sector ETF up 35%. He maintains a long-term bullish view on psychedelics due to large addressable market and regulatory progress, but his current focus is shifting to four other sectors for the second half of 2026, which are not detailed in the provided excerpt.
  • Psychedelics have been the author's best call in 2026, with Compass Pathways (CMPS) up ~100%+ and Definium (DFTX) up ~200%+ YTD.
  • The AdvisorShares Psychedelics ETF (PSIL) has climbed about 35% so far this year.
  • The author believes the addressable market for psychedelic-assisted therapies is enormous and still early stage, supporting a long-term positive outlook.
  • The article promises to identify four sectors (outside psychedelics) for the rest of 2026, but the full list is not included in the provided text.
Read time 1 min
Length 1,182 chars
Category finance
Ideas
Quoth the Raven Substack author, QTR’s Fringe Finance
Author notes CMPS is up ~100%+ YTD and states 'It’s still a sector I like over the long run' with a belief in enormous addressable market for psychedelic therapies.
Author notes CMPS is up ~100%+ YTD and states 'It’s still a sector I like over the long run' with a belief in enormous addressable market for psychedelic therapies. Risk: Regulatory setbacks or slower-than-expected adoption could reverse gains; valuation may be stretched after large run-up.
Quoth the Raven Substack author, QTR’s Fringe Finance
Author highlights DFTX as a named pick that is up ~200%+ YTD and reiterates long-term bullishness on the psychedelics sector.
Author highlights DFTX as a named pick that is up ~200%+ YTD and reiterates long-term bullishness on the psychedelics sector. Risk: Small-cap biotech volatility; clinical trial outcomes binary; liquidity risk.
Quoth the Raven Substack author, QTR’s Fringe Finance
Author references PSIL's 35% YTD gain and maintains a long-term favorable view on the psychedelics sector, which the ETF tracks.
Author references PSIL's 35% YTD gain and maintains a long-term favorable view on the psychedelics sector, which the ETF tracks. Risk: Sector concentration; regulatory and sentiment shifts could lead to sharp drawdowns.
More from QTR’s Fringe Finance

This newsletter, published July 05, 2026, features Quoth the Raven discussing CMPS, DFTX, PSIL. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Quoth the Raven  · Tickers: CMPS, DFTX, PSIL